Citigroup
OACCU

Citigroup’s Oaktree Acquisition Corp III Life Sciences Unit OACCU Stock Holding History

Citigroup’s Portfolio OACCU Stock Details OACCU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-50,900
Closed -$550K – 6376
2025
Q2 		$550K Hold
50,900
– – ﹤0.01% 3567
2025
Q1 		$528K Hold
50,900
– – ﹤0.01% 3646
2024
Q4 		$516K Buy
+50,900
New +$513K ﹤0.01% 3802

Other funds holding OACCU

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup's OACCU Position: Q3 2025 in Review

Citigroup sold out of Oaktree Acquisition Corp III Life Sciences Unit (OACCU) in Q3 2025, closing a stake of 50,900 shares — an estimated $550K sold.

Citigroup first reported a position in OACCU in Q4 2024 and held it in 3 quarters. The position peaked at $550K in Q2 2025. 5 funds tracked by Wall St. Rank hold OACCU as of Q3 2025.

  • Citigroup reported no remaining Oaktree Acquisition Corp III Life Sciences Unit position as of Q3 2025 after selling out during the quarter.
  • Citigroup sold 50,900 Oaktree Acquisition Corp III Life Sciences Unit shares in Q3 2025, an estimated $550K.
  • Citigroup first reported a position in Oaktree Acquisition Corp III Life Sciences Unit in Q4 2024 and held it in 3 quarters.
  • Citigroup's Oaktree Acquisition Corp III Life Sciences Unit position peaked at $550K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences Unit as of Q3 2025.

Based on Citigroup's 13F filing for Q3 2025, filed 10 Nov 2025.